A Phase 3 interventional study of Investigational Medical Product (IMP) administered in parent study in Osteoarthritis, sponsored by Pfizer. Completed at 79 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-30.
Sponsored by Pfizer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Osteoarthritis by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis · Pfizer.
Among the 39 studies in Osteoarthritis by Pfizer, this one is the 25th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2016, is one of 21 in phase 3, and was the 35th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →2 of the 39 studies in Osteoarthritis by Pfizer are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 265 across the 37 interventional studies. Of the 36 that completed or were terminated, 20 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 39 studies in Osteoarthritis by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study. The study is designed with a total duration of subject follow-up of 24 weeks after the total joint replacement surgery. There will be two methods of data collection utilized in this study: interview by site staff via the telephone and interactive web-response system (or paper if the subject has no access to the internet).
A4091064 is a long-term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057 or A4091058.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
long-term observational study of subjects from tanezumab parent study
Drug: Investigational Medical Product (IMP) administered in parent study
IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
Number of Participants With Surgeon's Assessment of Procedural Difficulty
Following the TJR surgery on Day 1, the orthopedic surgeon was asked to answer the following question: "taking into consideration the participant's medical history and physical condition prior to surgery would you classify the operative procedure as Uneventful, Minor complications or Major complications." Participants were reported based on these categories for knee, hip and shoulder joint. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Day 1
Number of Participants With Overall Satisfaction With Surgery as Assessed by the Self-Administered Patient Satisfaction (SAPS) Scale at Week 24
SAPS contained four questions; How satisfied are you with the 1) results of your surgery 2) results of surgery for improving pain 3) results of surgery for improving ability to do home or yard work, and 4) results of surgery for improving your ability to do recreational activities. Items scored on a 4-point Likert scale with response of 'very satisfied' (100 points), 'somewhat satisfied' (75 points), 'somewhat dissatisfied' (50 points), and 'very dissatisfied' (25 points). The scale score calculated as mean of the scores of individual items, ranging from 25 to 100, with higher scores indicating greater satisfaction. Here, number of participants are summarized as, satisfied (very satisfied and somewhat satisfied categories combined) and dissatisfied (somewhat dissatisfied and very dissatisfied categories combined). Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Week 24
Number of Participants With Post-Surgical Complications Upto Week 24
Post-surgical complications are adverse events occurring after TJR surgery that were considered clinically significant as assessed by investigator and attributable to the total joint replacement procedure. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Baseline up to Week 24
Number of Participants With Additional or Corrective Procedures Related to Total Joint Replacement Upto Week 24
Participants were asked whether they had been told by their orthopedic surgeon that additional or corrective procedures were necessary for their total joint replacement. Participants, who responded as yes have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Baseline up to Week 24
Number of Participants Who Participated in Physical Rehabilitation Activities Related to Total Joint Replacement Upto Week 24
Participants responded with a yes or no to the following question ''are you participating in physical rehabilitation activities related to your replaced joint''. Participants responded with a yes, have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Baseline up to Week 24
Change From Baseline in Average Pain Score in to be Replaced or Replaced Joints at Week 24
Participants assessed their average pain in to be replaced (pre-surgery) knee/ hip joint or in the replaced joint (post-surgery) in the past 24 hours using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Baseline, Week 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Baseline, Week 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 24
WOMAC: self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the replaced/to be replaced index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Baseline, Week 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in replaced/ to be replaced index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions, which may not be a whole (integer) number, scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function. Participants may have been counted more than once if they had TJR surgery in more than one joint.
Time frame: Baseline, Week 24
Change From Baseline in Shoulder Pain and Disability Index (SPADI) Score at Week 24
SPADI: self-administered questionnaire to measure pain and disability associated with shoulder pathology in participants with shoulder pain. It consists of two dimensions pain and function. Pain dimension:5 questions regarding severity of pain, scores ranged from 0=no pain to 10=worst pain imaginable, higher scores indicated extreme pain. Functional activities:8 questions to measure degree of difficulty with various activities of daily living that require upper extremity use, scores ranged from 0=no difficulty to 10=so difficult it requires help, higher scores=extreme difficulty. Pain and disability dimension score was calculated as the sum of non-missing scores divided by the maximum possible score (50 \[for pain\] and 80 \[for disability\]) multiplied by 100. A total score was calculated as the mean of two dimensions, ranged from 0=best to 100=worst, higher scores indicated worsening of condition.
Time frame: Baseline, Week 24
Number of Participants Who Used Concomitant Analgesic Medications
Time frame: Baseline up to Week 24
This study included participants from studies A4091056 (NCT02697773), A4091057 (NCT02709486) and A4091058 (NCT02528188) who had undergone a total joint replacement (TJR) surgery of knee, hip, or shoulder. During this study, if participant underwent an additional TJR surgery, then data for that additional TJR surgery was also assessed.
| Milestone | Placebo | Tanezumab Combined | NSAID |
|---|---|---|---|
| Started | 20 | 117 | 17 |
| Safety analysis set | 20 | 113 | 17 |
| Completed | 20 | 107 | 16 |
| Not completed | 0 | 10 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
| Withdrew: Enrolled but not evaluated | 0 | 4 | 0 |
Following the TJR surgery on Day 1, the orthopedic surgeon was asked to answer the following question: "taking into consideration the participant's medical history and physical condition prior to surgery would you classify the operative procedure as Uneventful, Minor complications or Major complications." Participants were reported based on these categories for knee, hip and shoulder joint. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| Participants | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Knee — Uneventful | 9 | 49 | 8 | 66 |
| Knee — Minor Complications | 0 | 2 | 0 | 2 |
| Knee — Major Complications | 0 | 0 | 0 | 0 |
| Hip — Uneventful | 8 | 37 | 4 | 49 |
| Hip — Minor Complications | 0 | 4 | 0 | 4 |
| Hip — Major Complications | 0 | 0 | 0 | 0 |
| Shoulder — Uneventful | 0 | 0 | 1 | 1 |
| Shoulder — Minor Complications | 0 | 0 | 0 | 0 |
| Shoulder — Major Complications | 0 | 0 | 0 | 0 |
SAPS contained four questions; How satisfied are you with the 1) results of your surgery 2) results of surgery for improving pain 3) results of surgery for improving ability to do home or yard work, and 4) results of surgery for improving your ability to do recreational activities. Items scored on a 4-point Likert scale with response of 'very satisfied' (100 points), 'somewhat satisfied' (75 points), 'somewhat dissatisfied' (50 points), and 'very dissatisfied' (25 points). The scale score calculated as mean of the scores of individual items, ranging from 25 to 100, with higher scores indicating greater satisfaction. Here, number of participants are summarized as, satisfied (very satisfied and somewhat satisfied categories combined) and dissatisfied (somewhat dissatisfied and very dissatisfied categories combined). Participants may have been counted more than once if they had TJR surgery in more than one joint.
| Participants | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Knee: Satisfaction with result of surgery — Satisfied | 9 | 53 | 5 | 67 |
| Knee: Satisfaction with result of surgery — Dissatisfied | 0 | 5 | 1 | 6 |
| Knee: Results of surgery for relieving pain — Satisfied | 9 | 52 | 5 | 66 |
| Knee: Results of surgery for relieving pain — Dissatisfied | 0 | 6 | 1 | 7 |
| Knee: Improving ability for home or yard work — Satisfied | 9 | 48 | 5 | 62 |
| Knee: Improving ability for home or yard work — Dissatisfied | 0 | 10 | 1 | 11 |
| Knee: Improving ability-recreational activities — Satisfied | 9 | 50 | 5 | 64 |
| Knee: Improving ability-recreational activities — Dissatisfied | 0 | 8 | 1 | 9 |
| Hip: Satisfaction with result of surgery — Satisfied | 9 | 40 | 6 | 55 |
| Hip: Satisfaction with result of surgery — Dissatisfied | 1 | 1 | 0 | 2 |
| Hip: Results of surgery for relieving pain — Satisfied | 9 | 41 | 6 | 56 |
| Hip: Results of surgery for relieving pain — Dissatisfied | 1 | 0 | 0 | 1 |
| Hip: Improving ability for home or yard work — Satisfied | 9 | 41 | 6 | 56 |
| Hip: Improving ability for home or yard work — Dissatisfied | 1 | 0 | 0 | 1 |
| Hip: Improving ability-recreational activities — Satisfied | 9 | 40 | 6 | 55 |
| Hip: Improving ability-recreational activities — Dissatisfied | 1 | 1 | 0 | 2 |
| Shoulder: Satisfaction with result of surgery — Satisfied | 0 | 0 | 1 | 1 |
| Shoulder: Satisfaction with result of surgery — Dissatisfied | 0 | 0 | 0 | 0 |
| Shoulder: Results of surgery for relieving pain — Satisfied | 0 | 0 | 1 | 1 |
| Shoulder: Results of surgery for relieving pain — Dissatisfied | 0 | 0 | 0 | 0 |
| Shoulder: Improving ability for home or yard work — Satisfied | 0 | 0 | 1 | 1 |
| Shoulder: Improving ability for home or yard work — Dissatisfied | 0 | 0 | 0 | 0 |
| Shoulder:Improving ability-recreational activities — Satisfied | 0 | 0 | 1 | 1 |
| Shoulder:Improving ability-recreational activities — Dissatisfied | 0 | 0 | 0 | 0 |
Post-surgical complications are adverse events occurring after TJR surgery that were considered clinically significant as assessed by investigator and attributable to the total joint replacement procedure. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| Participants | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Knee | 0 | 1 | 0 | 1 |
| Hip | 0 | 5 | 0 | 5 |
| Shoulder | 0 | 0 | 0 | 0 |
Participants were asked whether they had been told by their orthopedic surgeon that additional or corrective procedures were necessary for their total joint replacement. Participants, who responded as yes have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| Participants | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Knee | 0 | 4 | 0 | 4 |
| Hip | 0 | 5 | 1 | 6 |
| Shoulder | 0 | 0 | 0 | 0 |
Participants responded with a yes or no to the following question ''are you participating in physical rehabilitation activities related to your replaced joint''. Participants responded with a yes, have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| Participants | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Knee | 10 | 55 | 7 | 72 |
| Hip | 9 | 33 | 3 | 45 |
| Shoulder | 0 | 0 | 1 | 1 |
Participants assessed their average pain in to be replaced (pre-surgery) knee/ hip joint or in the replaced joint (post-surgery) in the past 24 hours using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| units on a scale | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Baseline: Knee | 6.00 ± 2.31 | 6.86 ± 2.14 | 6.80 ± 2.20 | 6.76 ± 2.16 |
| Baseline: Hip | 6.10 ± 2.13 | 6.81 ± 2.27 | 5.86 ± 3.44 | 6.60 ± 2.38 |
| Change at Week 24: Knee | -4.56 ± 1.24 | -5.32 ± 2.63 | -5.43 ± 2.51 | -5.24 ± 2.49 |
| Change at Week 24: Hip | -5.20 ± 2.30 | -5.67 ± 2.37 | -5.00 ± 4.10 | -5.52 ± 2.53 |
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| units on a scale | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Baseline: Knee | 4.66 ± 3.05 | 5.62 ± 2.33 | 6.11 ± 2.31 | 5.56 ± 2.41 |
| Baseline: Hip | 4.80 ± 2.61 | 5.97 ± 2.46 | 6.13 ± 1.98 | 5.80 ± 2.45 |
| Change at Week 24: Knee | -3.13 ± 1.74 | -4.50 ± 2.43 | -4.54 ± 3.15 | -4.34 ± 2.44 |
| Change at Week 24: Hip | -4.34 ± 2.52 | -4.92 ± 2.62 | -5.92 ± 2.40 | -4.91 ± 2.57 |
WOMAC: self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the replaced/to be replaced index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| units on a scale | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Baseline: Knee | 4.80 ± 2.78 | 5.75 ± 2.52 | 6.44 ± 2.58 | 5.71 ± 2.55 |
| Baseline: Hip | 4.70 ± 2.75 | 5.96 ± 2.69 | 5.25 ± 3.50 | 5.69 ± 2.77 |
| Change at Week 24: Knee | -1.78 ± 1.52 | -4.13 ± 2.58 | -3.43 ± 3.13 | -3.79 ± 2.62 |
| Change at Week 24: Hip | -4.00 ± 2.66 | -4.48 ± 2.87 | -3.80 ± 3.70 | -4.33 ± 2.86 |
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in replaced/ to be replaced index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions, which may not be a whole (integer) number, scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function. Participants may have been counted more than once if they had TJR surgery in more than one joint.
| units on a scale | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Baseline: Knee | 4.83 ± 2.99 | 5.82 ± 2.11 | 6.63 ± 1.98 | 5.79 ± 2.23 |
| Baseline: Hip | 5.56 ± 2.21 | 6.50 ± 2.22 | 6.86 ± 1.48 | 6.38 ± 2.17 |
| Change at Week 24: Knee | -2.69 ± 1.51 | -4.42 ± 2.19 | -4.59 ± 2.90 | -4.24 ± 2.24 |
| Change at Week 24: Hip | -4.64 ± 2.13 | -5.05 ± 2.44 | -5.95 ± 1.84 | -5.06 ± 2.33 |
SPADI: self-administered questionnaire to measure pain and disability associated with shoulder pathology in participants with shoulder pain. It consists of two dimensions pain and function. Pain dimension:5 questions regarding severity of pain, scores ranged from 0=no pain to 10=worst pain imaginable, higher scores indicated extreme pain. Functional activities:8 questions to measure degree of difficulty with various activities of daily living that require upper extremity use, scores ranged from 0=no difficulty to 10=so difficult it requires help, higher scores=extreme difficulty. Pain and disability dimension score was calculated as the sum of non-missing scores divided by the maximum possible score (50 \[for pain\] and 80 \[for disability\]) multiplied by 100. A total score was calculated as the mean of two dimensions, ranged from 0=best to 100=worst, higher scores indicated worsening of condition.
| units on a scale | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Baseline | — | — | 89.88 | 89.88 |
| Change at Week 24 | — | — | -89.88 | -89.88 |
| Participants | Placebo | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|
| Number of Participants Who Used Concomitant Analgesic Medications | 18 | 100 | 15 | 133 |
Collected over Baseline up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Tanezumab 2.5 mg | 0/52 (0%) | 5/52 (9.6%) | 9/52 (17.3%) |
| Tanezumab 2.5/5 mg | 0/8 (0%) | 3/8 (37.5%) | 3/8 (37.5%) |
| Tanezumab 5 mg | 0/53 (0%) | 7/53 (13.2%) | 9/53 (17%) |
| Tanezumab Combined | 0/113 (0%) | 15/113 (13.3%) | 21/113 (18.6%) |
| NSAID | 0/17 (0%) | 2/17 (11.8%) | 4/17 (23.5%) |
| All Participants | 0/150 (0%) | 17/150 (11.3%) | 25/150 (16.7%) |
| Event | Placebo | Tanezumab 2.5 mg | Tanezumab 2.5/5 mg | Tanezumab 5 mg | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|---|---|---|
| Colitis ischaemicGastrointestinal disorders | 0/20 | 0/52 | 1/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| Hiatus herniaGastrointestinal disorders | 0/20 | 0/52 | 1/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| Gastroenteritis viralInfections and infestations | 0/20 | 0/52 | 1/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/20 | 0/52 | 1/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/20 | 1/52 | 0/8 | 2/53 | 3/113 | 2/17 | 5/150 |
| Coronary artery occlusionCardiac disorders | 0/20 | 1/52 | 0/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| DiarrhoeaGastrointestinal disorders | 0/20 | 1/52 | 0/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| EnteritisGastrointestinal disorders | 0/20 | 1/52 | 0/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| Post procedural infectionInfections and infestations | 0/20 | 1/52 | 0/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| Periprosthetic fractureInjury, poisoning and procedural complications | 0/20 | 1/52 | 0/8 | 0/53 | 1/113 | 0/17 | 1/150 |
| Event | Placebo | Tanezumab 2.5 mg | Tanezumab 2.5/5 mg | Tanezumab 5 mg | Tanezumab Combined | NSAID | All Participants |
|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/20 | 0/52 | 1/8 | 2/53 | 3/113 | 0/17 | 3/150 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/20 | 1/52 | 1/8 | 0/53 | 2/113 | 0/17 | 2/150 |
| Urinary retentionRenal and urinary disorders | 0/20 | 0/52 | 1/8 | 1/53 | 2/113 | 0/17 | 2/150 |
| Procedural painInjury, poisoning and procedural complications | 0/20 | 3/52 | 0/8 | 6/53 | 9/113 | 0/17 | 9/150 |
| Atrioventricular block second degreeCardiac disorders | 0/20 | 0/52 | 0/8 | 0/53 | 0/113 | 1/17 | 1/150 |
| Coronary artery stenosisCardiac disorders | 0/20 | 0/52 | 0/8 | 0/53 | 0/113 | 1/17 | 1/150 |
| Chest painGeneral disorders | 0/20 | 0/52 | 0/8 | 0/53 | 0/113 | 1/17 | 1/150 |
| Peripheral swellingGeneral disorders | 0/20 | 0/52 | 0/8 | 0/53 | 0/113 | 1/17 | 1/150 |
| Drug hypersensitivityImmune system disorders | 0/20 | 0/52 | 0/8 | 0/53 | 0/113 | 1/17 | 1/150 |
| Joint swellingMusculoskeletal and connective tissue disorders | 0/20 | 1/52 | 0/8 | 0/53 | 1/113 | 1/17 | 2/150 |
Safety analysis set: all enrolled participants of this study who had received at least one dose of SC study medication during studies A4091056, A4091057 or A4091058, and who had a qualifying i.e. total (not partial) joint replacement surgery.
| Age, Continuous(Years) | Placebo | Tanezumab Combined | NSAID | Total |
|---|---|---|---|---|
| Mean | 65.26 ± 8.77 | 64.57 ± 8.18 | 62.94 ± 9.13 | 64.47 ± 8.33 |
| Sex/Gender, Customized(Participants) | Placebo | Tanezumab Combined | NSAID | Total |
|---|---|---|---|---|
| Male | 6 | 50 | 4 | 60 |
| Female | 13 | 62 | 13 | 88 |
| Unspecified | 1 | 1 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tanezumab Combined | NSAID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 3 | 7 |
| Not Hispanic or Latino | 18 | 109 | 14 | 141 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | Tanezumab Combined | NSAID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 6 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 6 | 3 | 9 |
| White | 17 | 100 | 14 | 131 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2016 to primary completion in Jul 2019, 34 months.
Results were first posted in Jul 2020, 1 year after primary completion.
Of 60 industry-sponsored phase 3 interventional studies under Osteoarthritis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 34 months is above that.
Counting every sponsor, half of 84 studies reached it within 17 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inosine Monophosphate